EA202192129A1 - Концентрированные жидкие фармацевтические составы фуросемида и способы их введения - Google Patents

Концентрированные жидкие фармацевтические составы фуросемида и способы их введения

Info

Publication number
EA202192129A1
EA202192129A1 EA202192129A EA202192129A EA202192129A1 EA 202192129 A1 EA202192129 A1 EA 202192129A1 EA 202192129 A EA202192129 A EA 202192129A EA 202192129 A EA202192129 A EA 202192129A EA 202192129 A1 EA202192129 A1 EA 202192129A1
Authority
EA
Eurasian Patent Office
Prior art keywords
furosemide
methods
pharmaceutical compositions
liquid pharmaceutical
administration
Prior art date
Application number
EA202192129A
Other languages
English (en)
Inventor
Альфредо Гросси
Бритт Костраба
Олатокумбо О. Лука Огунлее
Шеннон Терри
Франсискус Коппенхаген
Original Assignee
ЭсСиФАРМАСЬЮТИКАЛЗ ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭсСиФАРМАСЬЮТИКАЛЗ ИНК. filed Critical ЭсСиФАРМАСЬЮТИКАЛЗ ИНК.
Publication of EA202192129A1 publication Critical patent/EA202192129A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

В настоящем изобретении частично раскрыты жидкие фармацевтические составы, содержащие фуросемид или его фармацевтически приемлемую соль, один или более фармацевтически приемлемых наполнителей и фармацевтически приемлемый буфер. Также раскрыты способы лечения застоя, отека, перегрузки жидкостью или гипертензии у нуждающегося в нем пациента.
EA202192129A 2019-01-31 2020-01-30 Концентрированные жидкие фармацевтические составы фуросемида и способы их введения EA202192129A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962799215P 2019-01-31 2019-01-31
PCT/US2020/015799 WO2020160210A1 (en) 2019-01-31 2020-01-30 Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same

Publications (1)

Publication Number Publication Date
EA202192129A1 true EA202192129A1 (ru) 2021-10-19

Family

ID=69740677

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192129A EA202192129A1 (ru) 2019-01-31 2020-01-30 Концентрированные жидкие фармацевтические составы фуросемида и способы их введения

Country Status (14)

Country Link
US (10) US11998555B2 (ru)
EP (1) EP3917495A1 (ru)
JP (2) JP7465881B2 (ru)
KR (1) KR20210150360A (ru)
CN (2) CN113747881B (ru)
AU (1) AU2020214314A1 (ru)
BR (1) BR112021014637A2 (ru)
CA (1) CA3128033A1 (ru)
EA (1) EA202192129A1 (ru)
IL (1) IL285073A (ru)
MA (1) MA54865A (ru)
MX (2) MX2021009084A (ru)
SG (1) SG11202108280RA (ru)
WO (1) WO2020160210A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021009084A (es) 2019-01-31 2021-10-26 Scpharmaceuticals Inc Formulaciones farmaceuticas liquidas concentradas de furosemida y metodos para administrar las mismas.
WO2024151502A1 (en) * 2023-01-09 2024-07-18 Scpharmaceuticals Inc. Methods of treatment using loop diuretics

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663348A (en) 1985-07-02 1987-05-05 Warner-Lambert Co. Furosemide salts and pharmaceutical preparations thereof
US4698361A (en) 1986-05-28 1987-10-06 Schiena Michele G Di Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same
DE3623620A1 (de) 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
ES2076263T3 (es) * 1989-08-21 1995-11-01 American Cyanamid Co Formulacion farmaceutica inyectable estable, para acido folico y sales de leucovorina y procedimiento.
CA2109924A1 (en) 1991-05-30 1992-12-10 Janina Adamczyk Reagents containing a nonspecific binding blocker in ion-capture binding assays
US5633240A (en) 1994-09-01 1997-05-27 Academic Pharmaceuticals Parenteral solutions containing metolazone
IT1283608B1 (it) 1996-04-17 1998-04-22 Ricerche Di Schiena Snc Di Dr Composizione farmaceutica per la terapia orale diuretica ed antiipertensiva.
CN1068778C (zh) 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
ATE409280T1 (de) 2005-12-28 2008-10-15 Sensile Pat Ag Mikropumpe
PT2038252T (pt) 2006-07-12 2016-12-16 Univ Tennessee Res Found Acilanilidos substituidos e métodos de utilização dos mesmos
EP2022518A1 (en) 2007-08-07 2009-02-11 Sensile Pat AG Modular drug delivery device for administering discrete doses of a medicament
US7923447B2 (en) 2008-03-17 2011-04-12 Academic Pharmaceuticals Incorporated Parenteral solutions containing metolazone
EA022948B1 (ru) 2008-05-16 2016-03-31 Кортера, Инк. Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
CA2735660C (en) 2008-09-09 2017-05-30 Cima Labs Inc. Dosage forms for weakly ionizable compounds
WO2011028997A1 (en) 2009-09-04 2011-03-10 Minipumps Llc Adhesive skin patch with pump for subcutaneous drug delivery
WO2013059735A1 (en) 2011-10-19 2013-04-25 Mercator Medsystems, Inc. Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation
CN103371967A (zh) * 2012-04-17 2013-10-30 上海禾丰制药有限公司 呋塞米注射液及其制剂工艺
MX369832B (es) 2012-05-18 2019-11-22 Luoda Pharma Ltd Formulaciones líquidas que comprenden pimobendan y propilenglicol para el tratamiento de hipertensión y/o enfermedades cardiacas.
EP3799869A1 (en) 2013-04-05 2021-04-07 ScPharmaceuticals Inc. Pharmaceutical formulations for subcutaneous administration of furosemide
JP6323818B2 (ja) 2014-10-29 2018-05-16 日産自動車株式会社 燃料電池用電極触媒、燃料電池用電極触媒層、その製造方法ならびに当該触媒層を用いる膜電極接合体および燃料電池
WO2020120482A1 (en) 2018-12-10 2020-06-18 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
CN113271923A (zh) 2019-01-04 2021-08-17 Sq创新股份公司 呋塞米的药物组合物及其用途
WO2020141226A1 (en) 2019-01-04 2020-07-09 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
MX2021009084A (es) 2019-01-31 2021-10-26 Scpharmaceuticals Inc Formulaciones farmaceuticas liquidas concentradas de furosemida y metodos para administrar las mismas.

Also Published As

Publication number Publication date
JP2024086756A (ja) 2024-06-28
US20220378805A1 (en) 2022-12-01
MX2023012741A (es) 2024-02-27
US11571434B2 (en) 2023-02-07
KR20210150360A (ko) 2021-12-10
US11998555B2 (en) 2024-06-04
CA3128033A1 (en) 2020-08-06
CN113747881A (zh) 2021-12-03
US20220168323A1 (en) 2022-06-02
AU2020214314A1 (en) 2021-08-19
SG11202108280RA (en) 2021-08-30
IL285073A (en) 2021-09-30
US11559535B2 (en) 2023-01-24
US20220378806A1 (en) 2022-12-01
US12048709B2 (en) 2024-07-30
US20240316070A1 (en) 2024-09-26
MA54865A (fr) 2022-05-04
JP2022518900A (ja) 2022-03-17
MX2021009084A (es) 2021-10-26
BR112021014637A2 (pt) 2021-09-21
US20240316071A1 (en) 2024-09-26
EP3917495A1 (en) 2021-12-08
JP7465881B2 (ja) 2024-04-11
US11497755B2 (en) 2022-11-15
US20240299419A1 (en) 2024-09-12
US20240307417A1 (en) 2024-09-19
US20230277558A1 (en) 2023-09-07
CN113747881B (zh) 2024-05-14
CN118319852A (zh) 2024-07-12
US20240325411A1 (en) 2024-10-03
WO2020160210A1 (en) 2020-08-06
US20220096500A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
EA201992784A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201992329A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
PH12020551425A1 (en) Rimegepant for cgrp related disorders
EA201892657A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
MY187047A (en) Selective pyy compounds and uses thereof
EA201990425A1 (ru) Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
EA201992334A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
CO2022007953A2 (es) Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
EA201992782A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA202191239A1 (ru) Соединения и их применение для лечения дефицита 1-антитрипсина
EA201792591A1 (ru) Фармацевтические препараты
EA202192129A1 (ru) Концентрированные жидкие фармацевтические составы фуросемида и способы их введения
MA42016A1 (fr) Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4, utilisées pour le traitement d''affections inflammatoires oculaires
EA202190561A1 (ru) Препараты ag10
EA202090542A1 (ru) Высококонцентрированные лекарственные формы придопидина
JOP20210230A1 (ar) صياغات صيدلانية
CO2022005999A2 (es) Inhibidores del factor d del complemento para administración oral
EA201990095A1 (ru) КОНДЕНСИРОВАННЫЕ ТИОФЕНОВЫЕ ПРОИЗВОДНЫЕ, ПРИЕМЛЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NAPI-IIb
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение